Skip to content

Home
Immuno-Oncology
Therapies
- Approved Drugs
- Experimental Therapies
  - a
    - Actimmune
    - ABBV-181
    - ABBV-428
    - ABP798
    - Adagloxad Simolenin
    - ADU-741 (JNJ-64041809 )
    - ADXS-HER2
    - ADXS-PSA
    - AE37
    - AFM11
    - AFM13
    - AGEN1884
    - AGEN2034
    - ALKS 4230
    - AlloStim
    - AM0010 (Pegilodecakin)
    - AMG 211 (MEDI-565)
    - AMG 330
    - AMG 420
    - APVO414 (MOR209/ES414)
    - AST-VAC1
    - ATA520
    - AutoSynVax
  - b-c
  - D-F
  - G-I
    - GALE-301
    - Galinpepimut-S
    - Ganitumab
    - GBR 1342
    - GI-6207
    - GI-6301
    - GL-ONC1
    - Gliovac (ERC1671)
    - GP2
    - GRN-1201
    - GSK3174998
    - GWN323
    - HF10
    - ICT-107
    - ICT-121
    - IGN002
    - IMCgp100
    - IMP701
    - INCAGN1949
    - INO-1400
    - INO-3106
    - INO-5150
    - INO-9012
  - J-L
  - M-O
    - M7824
    - MAGE-A10 T-Cell Therapy
    - MBG453
    - MDNA55
    - MEDI0457
    - MEDI0562
    - MEDI0680
    - MGA012
    - MGD009
    - MK-4166
    - Mogamulizumab
    - MVA-BN Brachyury
    - MVI-118
    - NEO-PV-01
    - NeuVax (Nelipepimut-S)
    - NKR-2
    - NKTR-214
    - NY-ESO TCR
    - OncoVAX
    - ONCOS-102
  - P-S
    - PAN-301-1
    - PDR001
    - PDS0101
    - PF-04518600
    - PF-06801591
    - PNK-007
    - ProscaVax
    - PVRIG
    - Provenge (Sipuleucel-T)
    - REGN2810 (SAR439684)
    - REGN3767
    - Relatlimab
    - Reolysin
    - RG7802
    - RG7828
    - Rocapuldencel-T
    - rSIFN-co
    - SHR-1210
    - SL-701
    - SurVaxM
  - T-Z
    - TT12
    - Tedopi (OSE-2101)
    - Telomelysin (OBP-301)
    - TG4010
    - TPIV 200
    - TPIV200
    - Traumakine
    - TRX518
    - TSR-022
    - TSR-042
    - Utomilumab
    - ValloVax
    - Varlilumab
    - Vigil
    - Viagenpumatucel-L
    - VX15
    - VBI-1901
    - XmAb13676
    - VGX-3100
Categories
- T cells
- PD-1
- Melanoma
- Breast Cancer
- Cancer Vaccines
- FDA

Search for:

Profile

Home » Profile

[symposium-profile]

Search for:

Featured Posts

First Cancer Patient Dosed in Trial Investigating Immunotherapy ADXS-NEO

June 22, 2018

European Partnership Aims to Better Understand and Predict Immunotherapy Response

April 18, 2018

BeiGene Begins Administering Esophagus Cancer Immuno-oncology Therapy in Phase 3 Trial

February 6, 2018

Visit Immuno-Oncology News's profile on Pinterest.

Immuno-Oncology News

BioNews Services, LLC
3 W. Garden St.
Suite 354
Pensacola, FL 32502
Email: [email protected]
Phone: 1-800-936-1363

About Immuno-Oncology News
Keytruda (Pembrolizumab)
Contact Us
Privacy Policy
Terms of Service

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest